Top developments and predictions for the Life Sciences and Healthcare Sector in China

China

As we enter the Year of the Pig, we take a look back at the top 10 developments of 2018 and towards what lies ahead with our top 10 predictions of 2019, for you and your business operating in China.

This past year we saw the Chinese government focus on establishing policies and measures to promote faster avenues for the development and registration of urgently-needed drugs and innovative medical devices, as well as cracking-down on increasing drug prices, misleading advertising and product liability. We expect to see stricter regulations this coming year that fortify existing intellectual property rights protection and data protection regulations as the sector continues to develop its digital health initiatives.

We will be closely monitoring these ongoing developments and predictions during the course of the year, providing you with regular updates and analysis as they happen through our various free know-how platforms: our eAlert service, Law-Now, LinkedIn at ‘CMS Asia Pacific and CMS Life Sciences & Healthcare Sector’ and WeChat at ‘CMSAsia’.

If you would like to discuss any of the developments with us, please do let us know.